Discovery Platform

Relation Therapeutics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United Kingdom

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Undisclosed

Partner/Sponsor/Collaborator: Bill & Melinda Gates Foundation

Deal Size: $1.3 million Upfront Cash: Undisclosed

Deal Type: Funding September 01, 2020

Details:

Project RE will focus on finding therapies to tackle viral entry and replication and is co-led between Mila (Quebec AI Institute) and Relation Therapeutics.

Ardigen

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Ardigen, CVC Collaborate to Develop SARS-CoV-2 Vaccine

Lead Product(s): SARS-CoV-2 vaccine

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Vaccine

Partner/Sponsor/Collaborator: CVC

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration July 13, 2020

Details:

Ardigen's neoantigen prediction platform called "ArdImmune Vax" employs state of the art bioinformatics and Artificial Intelligence to identify an optimal set of neoantigens as targets for cancer vaccines or adoptive cell therapies.

Vaxxas

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

World Dairy Expo

Participation Not Confirmed

Update your events

Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate

Lead Product(s): Undisclosed

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Discovery Platform Product Type: Vaccine

Partner/Sponsor/Collaborator: Merck & Co. Inc.

Deal Size: $12.0 million Upfront Cash: Undisclosed

Deal Type: Agreement May 28, 2020

Details:

Under the collaboration agreement, originally signed in 2012, through the exercise of this option MSD gains exclusive worldwide rights to develop and commercialize an undisclosed vaccine utilizing Vaxxas’ HD-MAP technology.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Relation Therapeutics

Relation Therapeutics Teams up With Mila in Coalition to Identify Covid-19 Therapeutic Candidates

Ardigen

Ardigen, CVC Collaborate to Develop SARS-CoV-2 Vaccine

Vaxxas

Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System Activation Platform for Vaccine Candidate